Company: SMNR
Filing Date: 2025-12-03
Form Type: S-8
Source: 0001193125-25-306962
Chunk: 9

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-12-03
Form: S-8
Chunk 9
---
 Reoffer Prospectus is part of the Registration Statement that we filed with the Commission. We have provided to you in this Reoffer Prospectus a general description of the Selling Stockholders and the distribution of the shares. To the extent there is a conflict between the information contained in this Reoffer Prospectus and any of our subsequent filings with the Commission, the information in the document having the later date shall modify or supersede the earlier statement.

As permitted by the rules and regulations of the Commission, the Registration Statement of which this Reoffer Prospectus forms a part includes additional information not contained in this Reoffer Prospectus. You may read the Registration Statement and the other reports we file with the Commission at the Commission’s website or at our website as described above under the heading “Incorporation of Certain Information by Reference.”

Unless otherwise mentioned or unless the context requires otherwise, all references in this Reoffer Prospectus to “Semnur”, “the Company”, “the Registrant”, “we”, “us”, “our” or similar references mean Semnur Pharmaceuticals, Inc., formerly known as Denali Capital Acquisition Corp. (“Denali”), and its consolidated subsidiaries. References to “Legacy Semnur” refer to the private Delaware corporation that is now our wholly owned subsidiary, named Semnur, Inc. (formerly known as Semnur Pharmaceuticals, Inc.).

Semnur Pharmaceuticals, Inc.

On
September 22, 2025 (the “Closing Date”), Denali consummated the previously announced Business Combination pursuant to the terms of the Merger Agreement, by and among Denali, Denali Merger Sub Inc., a Delaware corporation and wholly
owned subsidiary of Denali (“Merger Sub”), and Legacy Semnur.

Pursuant to the Merger Agreement, (i) prior to the
closing, Denali changed its jurisdiction of incorporation by deregistrating as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the “Domestication”)
and (ii) at the closing, and following the Domestication, Merger Sub merged with and into Legacy Semnur (the “Merger”), with Legacy Semnur as the surviving company in the Merger, and, after giving effect to such Merger, Legacy
Semnur became a wholly owned subsidiary of Denali. The Merger was approved by Denali’s shareholders at a meeting held on September 3, 2025. In connection with the Business